Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas

European Journal of Cancer

Volumn 43, Issue 10, 2007, Pages 1630-1637

  Coosemans, A ^a   Nik, S Amini ^a   Caluwaerts, S ^a   Lambin, S ^a   Verbist, G ^a   Van Bree, R ^a   Schelfhout, V ^b   de Jonge, E ^c   Dalle, I ^d   Jacomen, G ^e   Cassiman, J J ^a   Moerman, Ph ^a   Vergote, I ^a   Amant, F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d Department of Pathology ^*  (Belgium)

^e Algemeen Ziekenhuis Sint Maarten   (Belgium)

Author keywords

Cytoplasmic expression; Sarcoma; Uterus; Wilms' tumour gene 1; WT1

Indexed keywords

CYTOPLASM PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN;

ARTICLE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERUS SARCOMA; WESTERN BLOTTING; WT1 GENE;

BLOTTING, WESTERN; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, WILMS TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; UP-REGULATION; UTERINE NEOPLASMS;

EID: 34249991721     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.04.008     Document Type: Article

References (48)

1. Hohenstein P., and Hastie N.D. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No. 2 (2006) R196-R201
2. Amini Nik S., Hohenstein P., Jadidizadeh A., et al. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Int J Cancer 114 (2005) 202-208
3. Carpentieri D.F., Nichols K., Chou P.M., Matthews M., Pawel B., and Huff D. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 15 (2002) 1080-1086
4. Oji Y., Miyoshi S., Maeda H., et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100 (2002) 297-303
5. Oji Y., Yamamoto H., Nomura M., et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94 (2003) 712-717
6. Oji Y., Inohara H., Nakazawa M., et al. Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94 (2003) 523-529
7. Oji Y., Miyoshi Y., Koga S., et al. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 94 (2003) 606-611
8. Oji Y., Yano M., Nakano Y., et al. Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24 (2004) 3103-3108
9. Oji Y., Nakamori S., Fujikawa M., et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95 (2004) 583-587
10. Oji Y., Suzuki T., Nakano Y., et al. Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95 (2004) 822-827
11. Silberstein G.B., Van Horn K., Strickland P., Roberts Jr. C.T., and Daniel C.W. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 94 (1997) 8132-8137
12. Ueda T., Oji Y., Naka N., et al. Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94 (2003) 271-276
13. Hendrickson M.R., Tavassoli F.A., Kempson R.L., McCluggage W.G., Haller U., and Kubick-Huch R.A. Tumours of the uterine corpus: Mesenchymal tumours and related lesions. In: Tavassoli F.A., and Devilee P. (Eds). WHO classification of tumours: pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon 233-244
14. Amant F., Vergote I., and Moerman Ph. The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma should be abandoned. Gynecol Oncol 95 (2004) 412-413
15. Ronnett B., Zaino R., and Elleson L. Endometrial carcinoma. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 5th ed. (2002), Springer-Verlag, New York 501-560
16. Amant F., Vloeberghs V., Woestenborghs H., Moerman P., and Vergote I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 90 (2003) 372-377
17. Amant F., Cadron I., Fuso L., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 98 (2005) 274-280
18. Egan J.A., Ionescu M.C., Eapen E., Jones J.G., and Marshall D.S. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 23 (2004) 119-122
19. Goldstein N.S., and Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 117 (2002) 541-545
20. Acs G., Pasha T., and Zhang P.J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23 (2004) 110-118
21. Al Hussaini M., Stockman A., Foster H., and McCluggage W.G. WT1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44 (2004) 109-115
22. Dupont J., Wang X., Marshall D.S., et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 94 (2004) 449-455
23. Heatley M.K. WT1 in ovarian and endometrioid serous carcinoma: a meta-analysis. Histopathology 46 (2005) 468
24. Hwang H., Quenneville L., Yaziji H., and Gown A.M. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 12 (2004) 122-126
25. Shimizu M., Toki T., Takagi Y., Konishi I., and Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 19 (2000) 158-163
26. Amant F., Dorfling C.M., Dreyer L., Vergote I., Lindeque B.G., and Van Rensburg E.J. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 11 (2001) 218-223
27. Amant F., de la Rey M., Dorfling C.M., et al. PTEN mutations in uterine sarcomas. Gynecol Oncol 85 (2002) 165-169
28. Amant F. Etiopathogenesis of uterine sarcomas: a study on genetic, hormonal and ethnic factors. Leuven: Leuven University Press; 2002. Ref Type: Thesis/Dissertation.
29. Agoff S.N., Grieco V.S., Garcia R., and Gown A.M. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol 9 (2001) 164-169
30. Sumathi V.P., Al Hussaini M., Connolly L.E., Fullerton L., and McCluggage W.G. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol 23 (2004) 241-247
31. Sotobori T., Ueda T., and Oji Y. Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer 106 (2006) 2233-2240
32. Oji Y., Miyoshi Y., Kiyotoh E., et al. Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol 34 (2004) 74-77
33. Dittadi R., Catozzi L., Gion M., et al. Comparison between western blotting, immunohistochemical and ELISA assay for p185neu quantitation in breast cancer specimens. Anticancer Res 13 (1993) 1821-1824
34. Niksic M., Slight J., Sanford J.R., Caceres J.F., and Hastie N.D. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 13 (2004) 463-471
35. Idelman G., Glaser T., Roberts Jr. C.T., and Werner H. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. J Biol Chem 278 (2003) 3474-3482
36. Maheswaran S., Park S., Bernard A., et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 90 (1993) 5100-5104
37. Nichols K.E., Re G.G., Yan Y.X., Garvin A.J., and Haber D.A. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 55 (1995) 4540-4543
38. Maheswaran S., Englert C., Bennett P., Heinrich G., and Haber D.A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9 (1995) 2143-2156
39. Little M., and Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 9 (1997) 209-225
40. Oji Y., Miyoshi S., Takahashi E., et al. Absence of mutations in the Wilms' tumor gene WT1 in de novo non-small cell lung cancers. Neoplasma 51 (2004) 17-20
41. Miyoshi Y., Ando A., Egawa C., et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8 (2002) 1167-1171
42. Makita M., Hiraki A., Azuma T., et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 8 (2002) 2626-2631
43. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51 (2000) 99-107
44. Van Driessche A., Gao L., Stauss H.J., et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 19 (2005) 1863-1871
45. Nakajima H., Kawasaki K., Oka Y., et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 53 (2004) 617-624
46. Oka Y., Tsuboi A., Elisseeva O.A., Udaka K., and Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2 (2002) 45-54
47. Oka Y., Tsuboi A., Murakami M., et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78 (2003) 56-61
48. Oka Y., Tsuboi A., Taguchi T., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 (2004) 13885-13890